US-based predictive analytics technology developer Lumiata has raised $10m in a round led by Intel Capital, the chipmaker’s corporate venturing unit, doubling its overall funding in the process.
Blue Cross Blue Shield Venture Partners, the corporate venturing fund sponsored by health insurance provider BlueCross and BlueShield Association, also took part in the round, as did venture capital firms Sandbox Industries and Khosla Ventures.
Founded in 2013, Lumiata is developing an artificial intelligence-equipped data analytics platform for healthcare provision. The Lumiata Medical Graph includes 260 million data points and around four terabytes of medical knowledge.
Lumiata closed a $10m series A round in 2014, after BlueCross BlueShield Venture Partners and Sandbox added $6m to an earlier $4m investment by Khosla Ventures.
Steve Agritelley, general manager of Intel’s Health and Life Sciences Group, said: “By integrating new data streams, such as [the internet of things], with traditional clinical data, Lumiata has the potential to bring a fresh approach to managing risk with healthcare analytics.
“We are excited by the opportunity to accelerate the deployment of predictive analytics and artificial intelligence throughout healthcare to drive more personalised value-based care.”